A citation-based method for searching scientific literature

John A Lupisella, Pravin S Shirude, Nicholas R Wurtz, Ricardo A Garcia. Semin Immunol 2022
Times Cited: 3







List of co-cited articles
11 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Formyl peptide receptor type 2 agonists to kick-start resolution pharmacology.
Mauro Perretti, Catherine Godson. Br J Pharmacol 2020
31
100

Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential.
Monika Maciuszek, Antonino Cacace, Eoin Brennan, Catherine Godson, Timothy M Chapman. Eur J Med Chem 2021
25
100

Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure.
Yoshikazu Asahina, Nicholas R Wurtz, Kazuto Arakawa, Nancy Carson, Kiyoshi Fujii, Kazunori Fukuchi, Ricardo Garcia, Mei-Yin Hsu, Junichi Ishiyama, Bruce Ito,[...]. J Med Chem 2020
30
66

Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution.
Eric L Campbell, Nancy A Louis, Sarah E Tomassetti, Geraldine O Canny, Makoto Arita, Charles N Serhan, Sean P Colgan. FASEB J 2007
150
66

Preservation of Post-Infarction Cardiac Structure and Function via Long-Term Oral Formyl Peptide Receptor Agonist Treatment.
Ricardo A García, Bruce R Ito, John A Lupisella, Nancy A Carson, Mei-Yin Hsu, Gayani Fernando, Madeleine Heroux, Michel Bouvier, Elizabeth Dierks, Ellen K Kick,[...]. JACC Basic Transl Sci 2019
25
66

Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice.
Cheng Xue Qin, Lauren T May, Renming Li, Nga Cao, Sarah Rosli, Minh Deo, Amy E Alexander, Duncan Horlock, Jane E Bourke, Yuan H Yang,[...]. Nat Commun 2017
88
66

Resolvin D1 binds human phagocytes with evidence for proresolving receptors.
Sriram Krishnamoorthy, Antonio Recchiuti, Nan Chiang, Stephanie Yacoubian, Chih-Hao Lee, Rong Yang, Nicos A Petasis, Charles N Serhan. Proc Natl Acad Sci U S A 2010
532
66

Resolution of inflammation: the beginning programs the end.
Charles N Serhan, John Savill. Nat Immunol 2005
66

Resolvin E1 and protectin D1 activate inflammation-resolution programmes.
Jan M Schwab, Nan Chiang, Makoto Arita, Charles N Serhan. Nature 2007
850
66


Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949.
Anna K Stalder, Dominik Lott, Daniel S Strasser, Hans G Cruz, Andreas Krause, Peter M A Groenen, Jasper Dingemanse. Br J Clin Pharmacol 2017
35
66

Maresin-1 resolution with RORα and LGR6.
Dong-Soon Im. Prog Lipid Res 2020
14
33

Total synthesis and bioactivity of resolvin E2.
Seiji Ogawa, Daisuke Urabe, Yoshiyuki Yokokura, Hiroyuki Arai, Makoto Arita, Masayuki Inoue. Org Lett 2009
47
33

Lipid mediator class switching during acute inflammation: signals in resolution.
B D Levy, C B Clish, B Schmidt, K Gronert, C N Serhan. Nat Immunol 2001
994
33

Lipoxins: revelations on resolution.
B McMahon, S Mitchell, H R Brady, C Godson. Trends Pharmacol Sci 2001
106
33

Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-271 by MAPK-activated protein kinase 2 (MK2).
Oliver Werz, Dagmar Szellas, Dieter Steinhilber, Olof Rådmark. J Biol Chem 2002
96
33


Lipoxin A4: a new class of ligand for the Ah receptor.
C M Schaldach, J Riby, L F Bjeldanes. Biochemistry 1999
194
33


Diversity of macrophage phenotypes and responses in atherosclerosis.
Hiroyuki Jinnouchi, Liang Guo, Atsushi Sakamoto, Sho Torii, Yu Sato, Anne Cornelissen, Salome Kuntz, Ka Hyun Paek, Raquel Fernandez, Daniela Fuller,[...]. Cell Mol Life Sci 2020
59
33

Lipoxin and resolvin biosynthesis is dependent on 5-lipoxygenase activating protein.
Christoph Lehmann, Julia Homann, Ann-Katrin Ball, René Blöcher, Thea K Kleinschmidt, Devaraj Basavarajappa, Carlo Angioni, Nerea Ferreirós, Ann-Kathrin Häfner, Olof Rådmark,[...]. FASEB J 2015
55
33

Atherosclerosis.
Peter Libby, Julie E Buring, Lina Badimon, Göran K Hansson, John Deanfield, Márcio Sommer Bittencourt, Lale Tokgözoğlu, Eldrin F Lewis. Nat Rev Dis Primers 2019
839
33

The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution.
Charles N Serhan, Nan Chiang, Jesmond Dalli. Semin Immunol 2015
342
33


Resolvin D1 Ameliorates Nicotinamide-streptozotocin-induced Type 2 Diabetes Mellitus by its Anti-inflammatory Action and Modulating PI3K/Akt/mTOR Pathway in the Brain.
Siresha Bathina, Naveen K V Gundala, Poorani Rhenghachar, Sailaja Polavarapu, Anasuya D Hari, Monika Sadananda, Undurti N Das. Arch Med Res 2020
28
33


5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease.
Olof Rådmark, Oliver Werz, Dieter Steinhilber, Bengt Samuelsson. Biochim Biophys Acta 2015
292
33

Synthesis, biological evaluation, molecular modeling, and structural analysis of new pyrazole and pyrazolone derivatives as N-formyl peptide receptors agonists.
Claudia Vergelli, Andrei I Khlebnikov, Letizia Crocetti, Gabriella Guerrini, Niccolò Cantini, Liliya N Kirpotina, Igor A Schepetkin, Agostino Cilibrizzi, Mark T Quinn, Patrizia Rossi,[...]. Chem Biol Drug Des 2021
4
33


Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome.
Charles N Serhan, Jesmond Dalli, Romain A Colas, Jeremy W Winkler, Nan Chiang. Biochim Biophys Acta 2015
285
33

Resolution of Inflammation Through the Lipoxin and ALX/FPR2 Receptor Pathway Protects Against Abdominal Aortic Aneurysms.
Marcelo H Petri, Silke Thul, Teodora Andonova, Moritz Lindquist-Liljeqvist, Hong Jin, Nikolaos-Taxiarchis Skenteris, Hildur Arnardottir, Lars Maegdefessel, Kenneth Caidahl, Mauro Perretti,[...]. JACC Basic Transl Sci 2018
31
33

Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease.
Daniel Pettersen, Johan Broddefalk, Hans Emtenäs, Martin A Hayes, Malin Lemurell, Marianne Swanson, Johan Ulander, Carl Whatling, Carl Amilon, Hans Ericsson,[...]. J Med Chem 2019
17
33

Molecular circuits of resolution: formation and actions of resolvins and protectins.
Gerard L Bannenberg, Nan Chiang, Amiram Ariel, Makoto Arita, Eric Tjonahen, Katherine H Gotlinger, Song Hong, Charles N Serhan. J Immunol 2005
512
33

High prevalence of COPD in atherosclerosis patients.
Izabela Tuleta, Tarik Farrag, Laura Busse, Carmen Pizarro, Christian Schaefer, Simon Pingel, Georg Nickenig, Dirk Skowasch, Nadjib Schahab. Int J Chron Obstruct Pulmon Dis 2017
12
33

The resolvin D1 analogue controls maturation of dendritic cells and suppresses alloimmunity in corneal transplantation.
Jing Hua, Yiping Jin, Yihe Chen, Takenori Inomata, HyunSoo Lee, Sunil K Chauhan, Nicos A Petasis, Charles N Serhan, Reza Dana. Invest Ophthalmol Vis Sci 2014
44
33

Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators.
Charles N Serhan, Nan Chiang, Thomas E Van Dyke. Nat Rev Immunol 2008
33

Protectin DX, a double lipoxygenase product of DHA, inhibits both ROS production in human neutrophils and cyclooxygenase activities.
Miao Liu, Tarek Boussetta, Karama Makni-Maalej, Michèle Fay, Fathi Driss, Jamel El-Benna, Michel Lagarde, Michel Guichardant. Lipids 2014
50
33

Phosphorylation by protein kinase a inhibits nuclear import of 5-lipoxygenase.
Ming Luo, Sandra M Jones, Nicolas Flamand, David M Aronoff, Marc Peters-Golden, Thomas G Brock. J Biol Chem 2005
64
33

Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes.
Charles N Serhan, Katherine Gotlinger, Song Hong, Yan Lu, Jeffrey Siegelman, Tamara Baer, Rong Yang, Sean P Colgan, Nicos A Petasis. J Immunol 2006
331
33

Resolvins and protectins in inflammation resolution.
Charles N Serhan, Nicos A Petasis. Chem Rev 2011
626
33

BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics.
R Müller-Peddinghaus, C Kohlsdorfer, P Theisen-Popp, R Fruchtmann, E Perzborn, B Beckermann, K Bühner, H J Ahr, K H Mohrs. J Pharmacol Exp Ther 1993
39
33

Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions.
Charles N Serhan, Rong Yang, Kimberly Martinod, Kie Kasuga, Padmini S Pillai, Timothy F Porter, Sungwhan F Oh, Matthew Spite. J Exp Med 2009
579
33

Stereoselective Synthesis of Maresin-like Lipid Mediators.
Song Hong, Yan Lu, Masao Morita, Shun Saito, Yuichi Kobayashi, Bokkyoo Jun, Nicolas G Bazan, Xiaoming Xu, Yapin Wang. Synlett 2019
3
33

1
100

Maresin 1 Mitigates Inflammatory Response and Protects Mice from Sepsis.
Ruidong Li, Yaxin Wang, Zhijun Ma, Muyuan Ma, Di Wang, Gengchen Xie, Yuping Yin, Peng Zhang, Kaixiong Tao. Mediators Inflamm 2016
34
33


Insights into the Activation Mechanism of the ALX/FPR2 Receptor.
Vinicius Schmitz Nunes, Alexandre P Rogério, Odonírio Abrahão. J Phys Chem Lett 2020
4
33

Experimental modeling of cornea wound healing in diabetes: clinical applications and beyond.
Yashan Bu, Kendrick Co Shih, Sum Sum Kwok, Yau Kei Chan, Amy Cheuk-Yin Lo, Tommy Chung Yan Chan, Vishal Jhanji, Louis Tong. BMJ Open Diabetes Res Care 2019
19
33

The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype.
Jesmond Dalli, Min Zhu, Nikita A Vlasenko, Bin Deng, Jesper Z Haeggström, Nicos A Petasis, Charles N Serhan. FASEB J 2013
181
33

The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo.
Nan Chiang, Charles N Serhan, Sven-Erik Dahlén, Jeffrey M Drazen, Douglas W P Hay, G Enrico Rovati, Takao Shimizu, Takehiko Yokomizo, Charles Brink. Pharmacol Rev 2006
364
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.